Simon Bailey

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9461723/publications.pdf

Version: 2024-02-01

54 papers	4,365 citations	257450 24 h-index	223800 46 g-index
54 all docs	54 docs citations	54 times ranked	5943 citing authors

#	Article	IF	Citations
1	Burkitt's lymphoma. Lancet, The, 2012, 379, 1234-1244.	13.7	486
2	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathologica, 2016, 131, 821-831.	7.7	478
3	Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathologica, 2011, 121, 381-396.	7.7	474
4	Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet Oncology, The, 2017, 18, 958-971.	10.7	384
5	Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. Journal of Clinical Oncology, 2013, 31, 2927-2935.	1.6	381
6	Divergent clonal selection dominates medulloblastoma at recurrence. Nature, 2016, 529, 351-357.	27.8	266
7	Definition of Disease-Risk Stratification Groups in Childhood Medulloblastoma Using Combined Clinical, Pathologic, and Molecular Variables. Journal of Clinical Oncology, 2011, 29, 1400-1407.	1.6	263
8	Cytogenetic Prognostication Within Medulloblastoma Subgroups. Journal of Clinical Oncology, 2014, 32, 886-896.	1.6	263
9	Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. Acta Neuropathologica, 2019, 138, 309-326.	7.7	180
10	Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease. Cancer Cell, 2015, 27, 72-84.	16.8	165
11	Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. Neuro-Oncology, 2017, 19, 1542-1552.	1.2	130
12	MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathologica, 2012, 123, 501-513.	7.7	87
13	Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity. Nature Communications, 2020, 11, 4324.	12.8	75
14	TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity. Pharmacogenetics and Genomics, 2017, 27, 213-222.	1.5	51
15	SIOP PODC adapted treatment recommendations for standard-risk medulloblastoma in low and middle income settings. Pediatric Blood and Cancer, 2015, 62, 553-564.	1.5	50
16	A framework to develop adapted treatment regimens to manage pediatric cancer in lowâ€•and middleâ€•income countries: The Pediatric Oncology in Developing Countries (PODC) Committee of the International Pediatric Oncology Society (SIOP). Pediatric Blood and Cancer, 2017, 64, e26879.	1.5	48
17	Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study. The Lancet Child and Adolescent Health, 2020, 4, 865-874.	5.6	48
18	Hypercalcemia in Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2009, 31, 424-427.	0.6	46

#	Article	IF	Citations
19	Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. Journal of Neuro-Oncology, 2017, 132, 255-266.	2.9	42
20	Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study. Neuro-Oncology, 2013, 15, 1236-1243.	1.2	41
21	Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?. Journal of Neuro-Oncology, 2019, 145, 177-184.	2.9	36
22	Application of pattern recognition techniques for classification of pediatric brain tumors by in vivo 3T ¹Hâ€MR spectroscopyâ€"A multiâ€center study. Magnetic Resonance in Medicine, 2018, 79, 2359-2366.	3.0	29
23	Histologically defined central nervous system primitive neuro-ectodermal tumours (CNS-PNETs) display heterogeneous DNA methylation profiles and show relationships to other paediatric brain tumour types. Acta Neuropathologica, 2013, 126, 943-946.	7.7	28
24	Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse. Neuro-Oncology, 2022, 24, 153-165.	1.2	28
25	Kaposiâ€™s sarcoma in children: An open randomised trial of vincristine, oral etoposide and a combination of vincristine and bleomycin. European Journal of Cancer, 2014, 50, 1472-1481.	2.8	27
26	Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients. Neuro-Oncology Advances, 2021, 3, vdab013.	0.7	27
27	Sporadic and endemic Burkitt lymphoma have frequent FOXO1 mutations but distinct hotspots in the AKT recognition motif. Blood Advances, 2019, 3, 2118-2127.	5.2	23
28	SIOP PODC Adapted treatment guidelines for low grade gliomas in low and middle income settings. Pediatric Blood and Cancer, 2017, 64, e26737.	1.5	21
29	Outcome at the end of treatment of patients with common and curable childhood cancer types in Blantyre, Malawi. Pediatric Blood and Cancer, 2020, 67, e28322.	1.5	17
30	Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Liâ€“Fraumeni syndrome. Leukemia, 2021, 35, 1475-1479.	7.2	17
31	Incidence and survival of children and young people with central nervous system embryonal tumours in the North of England, 1990â€“2013. European Journal of Cancer, 2016, 61, 36-43.	2.8	16
32	The use of anthracyclines in the treatment of endemic Burkitt lymphoma. British Journal of Haematology, 2017, 177, 984-990.	2.5	16
33	Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. Cancers, 2022, 14, 374.	3.7	16
34	Outcome is unchanged by adding vincristine upfront to the Malawi 28â€day protocol for endemic Burkitt lymphoma. Pediatric Blood and Cancer, 2015, 62, 1929-1934.	1.5	15
35	Intracystic interferon therapy in childhood craniopharyngioma: who, when and how?. Clinical Endocrinology, 2015, 82, 29-34.	2.4	13
36	Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment. Cancers, 2022, 14, 126.	3.7	12

#	Article	IF	Citations
37	A School Passport as Part of a Protocol to Assist Educational Reintegration After Medulloblastoma Treatment in Childhood. Pediatric Blood and Cancer, 2016, 63, 1636-1642.	1.5	11
38	Treating childhood acute lymphoblastic leukemia in Malawi. Haematologica, 2013, 98, e1-e3.	3.5	9
39	Advanced molecular pathology for rare tumours: A national feasibility study and model for centralised medulloblastoma diagnostics. Neuropathology and Applied Neurobiology, 2021, 47, 736-747.	3.2	9
40	SIOP PODCâ€“adapted treatment guidelines for craniopharyngioma in lowâ€•and middleâ€•income settings. Pediatric Blood and Cancer, 2023, 70, e28493.	1.5	8
41	Triple therapy of vincristine, bleomycin and etoposide for children with Kaposi sarcoma: Results of a study in Malawian children. Pediatric Blood and Cancer, 2018, 65, e26841.	1.5	7
42	Metabolite selection for machine learning in childhood brain tumour classification. NMR in Biomedicine, 2022, 35, e4673.	2.8	7
43	â€œThey've got a lot of needs and I don't think they're being met fullyâ€• A qualitative study of the multiâ€•professional team approach to the management of children with optic pathway gliomas. Pediatric Blood and Cancer, 2018, 65, e27377.	1.5	6
44	Central nervous system lesions in Malawian children: identifying the treatable. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2012, 106, 567-569.	1.8	4
45	Developmental delay and progressive seizures in 2â€•monthâ€•old child with diffuse MRI abnormalities. Brain Pathology, 2022, 32, e13049.	4.1	2
46	Challenges of starting treatment protocols for acute lymphoblastic leukaemia in a lowâ€•income setting â€” the Blantyre experience. British Journal of Haematology, 2020, 191, e87-e90.	2.5	1
47	Perioperative corticosteroid use in paediatric neuro-oncology. Child's Nervous System, 2021, 37, 3669-3671.	1.1	1
48	LGG-09. A Nationwide Service Evaluation of Safety, Radiologic and Visual Outcome Refining Bevacizumab-based Treatments in Children with Progressive Low-Grade Glioma. Neuro-Oncology, 2022, 24, i89-i89.	1.2	1
49	The importance of biopsy following radiological diagnosis of relapsed medulloblastoma. British Journal of Neurosurgery, 2012, 26, 542-544.	0.8	0
50	Global Challenges in Pediatric Neuro-Oncology. , 2018, , 403-426.		0
51	MBRS-29. IN-VIVO METABOLITE PROFILES FOR THE NON-INVASIVE AND RAPID IDENTIFICATION OF MOLECULAR SUBGROUP IN MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i134-i134.	1.2	0
52	HGG-49. Gliomatosis cerebri in children: A collaborative report from the European Society for Pediatric Oncology (SIOPE). Neuro-Oncology, 2022, 24, i72-i73.	1.2	0
53	MEDB-43. Development of a bioinformatics pipeline for identification of differential DNA methylation events associated with medulloblastoma relapse. Neuro-Oncology, 2022, 24, i115-i115.	1.2	0
54	MEDB-49. Relapsed SHH medulloblastomas in young children. Are there alternatives to full-dose craniospinal irradiation?. Neuro-Oncology, 2022, 24, i117-i117.	1.2	0